Scarica l'app Stockscreener
6.76
3.52%
0.23
Dopo l'orario di chiusura:
6.90
0.14
+2.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PRTA Giù?
Forum
Previsione
Precedente Chiudi:
$6.53
Aprire:
$6.685
Volume 24 ore:
457.76K
Relative Volume:
0.27
Capitalizzazione di mercato:
$363.87M
Reddito:
$217.25M
Utile/perdita netta:
$-50.92M
Rapporto P/E:
-6.76
EPS:
-1
Flusso di cassa netto:
$-100.85M
1 W Prestazione:
+6.96%
1M Prestazione:
+11.55%
6M Prestazione:
-56.33%
1 anno Prestazione:
-72.19%
Intervallo 1D:
$6.68
$6.84
Intervallo di 1 settimana:
$6.24
$6.84
Portata 52W:
$4.32
$25.42
Prothena Corporation Plc Stock (PRTA) Company Profile
Nome
Prothena Corporation Plc
Settore
Industria
Telefono
011-353-1-236-2500
Indirizzo
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Confronta PRTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
6.76 | 351.49M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-27 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-01-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-04-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-27 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-11-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-06-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Reiterato | Oppenheimer | Outperform |
| 2021-05-26 | Iniziato | Citigroup | Buy |
| 2021-02-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-12-07 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Downgrade | Jefferies | Buy → Hold |
| 2018-04-05 | Reiterato | Barclays | Overweight |
| 2017-11-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2017-09-29 | Reiterato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Jefferies | Buy |
| 2017-04-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-12-21 | Iniziato | SunTrust | Buy |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-08-04 | Reiterato | Barclays | Overweight |
| 2016-05-13 | Iniziato | Barclays | Overweight |
| 2016-02-19 | Reiterato | Wedbush | Outperform |
| 2016-01-21 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Prothena Corporation Plc Borsa (PRTA) Ultime notizie
What analysts say about Prothena Corporation plc stockExplosive trading opportunities - Autocar Professional
Prothena Corporation plc (NASDAQ:PRTA) Receives $31.50 Average Price Target from Analysts - Defense World
Prothena Corporation plc Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com
Is Prothena Corporation plc a good long term investmentExceptional gains - jammulinksnews.com
What drives Prothena Corporation plc stock priceRecord-breaking gains - jammulinksnews.com
How to Take Advantage of moves in (PRTA) - news.stocktradersdaily.com
Why Prothena Corporation plc stock attracts strong analyst attentionFree Smart Investment Opportunities - Newser
What makes Prothena Corporation plc stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
How Prothena Corporation plc stock performs during market volatilityFree Capital Allocation Plans - Newser
Cambridge Investment Research Advisors Inc. Acquires Shares of 10,164 Prothena Corporation plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? - sharewise.com
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - MSN
Prothena to lay off majority of staff; Zealand shares obesity drug data - BioPharma Dive
Peninsula biotech will cut half its workforce, but partner takes Parkinson's drug into late-stage trial - The Business Journals
Prothena announces 63% workforce reduction following birtamimab halt - Investing.com
Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus
Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus
Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks
Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus
Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus
Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus
Prothena to cut workforce by 63% amid strategic review - Investing.com
Prothena announces corporate restructuring - MarketScreener
Prothena Announces Corporate Restructuring - Business Wire
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World
Roche And Prothena: Why Moving On Makes Sense (OTCMKTS:RHHBY) - Seeking Alpha
(PRTA) Trading Signals - news.stocktradersdaily.com
Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX
Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha
Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks
Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com
Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus
Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com
Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa
Prothena Corporation Plc Azioni (PRTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):